GwÃ©naÃ«l Le Teuff

List of Publications by Year
in descending order

52 papers	2,927 citations	279798 23 h-index	189892 50 g-index
57 all docs	57 docs citations	57 times ranked	5659 citing authors

#	Article	IF	Citations
1	A two‐stage drop‐the‐losers design for time‐to‐event outcome using a historical control arm. Pharmaceutical Statistics, 2022, 21, 268-288.	1.3	0
2	Impact of young age on platinum response in women with epithelial ovarian cancer: Results of a large single-institution registry. Gynecologic Oncology, 2021, 160, 77-82.	1.4	2
3	Screening for SARS-CoV-2 by RT-PCR: Saliva or nasopharyngeal swab? Rapid review and meta-analysis. PLoS ONE, 2021, 16, e0253007.	2.5	38
4	A frequentist one-step model for a simple network meta-analysis of time-to-event data in presence of an effect modifier. PLoS ONE, 2021, 16, e0259121.	2.5	3
5	Prognostic Clinical and Biologic Features for Overall Survival after Relapse in Childhood Medulloblastoma. Cancers, 2021, 13, 53.	3.7	10
6	Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study. Pediatric Blood and Cancer, 2020, 67, e28032.	1.5	17
7	WHO grade has no prognostic value in the pediatric high-grade glioma included in the HERBY trial. Neuro-Oncology, 2020, 22, 116-127.	1.2	26
8	Group sequential adaptive designs in series of time-to-event randomised trials in rare diseases: A simulation study. Statistical Methods in Medical Research, 2020, 29, 1483-1498.	1.5	2
9	Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes. JAMA Oncology, 2020, 6, 206.	7.1	22
10	Phase I study of vinblastine in combination with nilotinib in children, adolescents, and young adults with refractory or recurrent low-grade glioma. Neuro-Oncology Advances, 2020, 2, vdaa075.	0.7	2
11	Identification of international metastatic renal cell carcinoma database consortium (IMDC) intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma. Oncotarget, 2020, 11, 4582-4592.	1.8	14
12	High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008. Journal of Clinical Oncology, 2019, 37, 3192-3202.	1.6	84
13	CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method. Computer Methods and Programs in Biomedicine, 2019, 176, 211-223.	4.7	0
14	Sarcome-13/OS2016 trial protocol: a multicentre, randomised, open-label, phase II trial of mifamurtide combined with postoperative chemotherapy for patients with newly diagnosed high-risk osteosarcoma. BMJ Open, 2019, 9, e025877.	1.9	23
15	A new prognostic model for survival in second line for metastatic renal cell carcinoma: development and external validation. Angiogenesis, 2019, 22, 383-395.	7.2	5
16	TP53 Pathway Alterations Drive Radioresistance in Diffuse Intrinsic Pontine Gliomas (DIPG). Clinical Cancer Research, 2019, 25, 6788-6800.	7.0	66
17	LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non‐small-cell Lung Cancer. Clinical Lung Cancer, 2019, 20, 66-73.e6.	2.6	19
18	Tumor Mutation Burden as a Biomarker in Resected Non‐Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 2995-3006.	1.6	223

#	Article	IF	Citations
19	DIPG-20. PRE-RANDOMISATION CENTRAL REVIEW AND REAL-TIME BIOMARKERS SCREENING IN THE MULTICENTRE BIOLOGICAL MEDICINE FOR DIPG ERADICATION (BIOMEDE) TRIAL: LESSONS LEARNT FROM THE FIRST 120 BIOPSIES. Neuro-Oncology, 2018, 20, i52-i53.	1.2	2
20	Variations in the breast reconstruction rate in France: A nationwide study of 19,466 patients based on the French medico-administrative database. Breast, 2018, 42, 74-80.	2.2	15
21	A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High‐Dose Methotrexate: Data From the OS2006/Sarcoma‐09 Trial. Journal of Clinical Pharmacology, 2018, 58, 1541-1549.	2.0	31
22	Identification of IMDC intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma (ccRCC).. Journal of Clinical Oncology, 2018, 36, e16577-e16577.	1.6	1
23	Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids. European Journal of Cancer, 2017, 75, 259-267.	2.8	39
24	Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre. European Journal of Cancer, 2017, 79, 185-192.	2.8	24
25	Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study. European Journal of Cancer, 2017, 80, 55-62.	2.8	18
26	Bayesian survival analysis in clinical trials: What methods are used in practice?. Clinical Trials, 2017, 14, 78-87.	1.6	18
27	Integrating Tenascin-C protein expression and 1q25 copy number status in pediatric intracranial ependymoma prognostication: A new model for risk stratification. PLoS ONE, 2017, 12, e0178351.	2.5	15
28	Inter and intra-tumor heterogeneity of PD-L1 and MET expression in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2017, 35, 4569-4569.	1.6	17
29	Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours. European Journal of Cancer, 2016, 69, 151-157.	2.8	31
30	Prognostic and Predictive Effect of TP53 Mutations in Patients with Non‐Small Cell Lung Cancer from Adjuvant Cisplatin‐Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis. Journal of Thoracic Oncology, 2016, 11, 850-861.	1.1	78
31	New insights into the evaluation of randomized controlled trials for rare diseases over a long‐term research horizon: a simulation study. Statistics in Medicine, 2016, 35, 3245-3258.	1.6	8
32	Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non‐Small-Cell Lung Cancer. Journal of Clinical Oncology, 2016, 34, 1223-1230.	1.6	300
33	Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel‐Lindau Gene Mutation Status. European Urology, 2016, 70, 623-632.	1.9	115
34	Efficacy of busulfan-melphalan high dose chemotherapy consolidation (BuMel) in localized high-risk Ewing sarcoma (ES): Results of EURO-EWING 99-R2 randomized trial (EE99R2Loc).. Journal of Clinical Oncology, 2016, 34, 11000-11000.	1.6	10
35	Efficacy of busulfan-melphalan high dose chemotherapy consolidation (BuMel) compared to conventional chemotherapy combined with lung irradiation in ewing sarcoma (ES) with primary lung metastases: Results of EURO-EWING 99-R2pulm randomized trial (EE99R2pul).. Journal of Clinical Oncology, 2016, 34, 11001-11001.	1.6	17
36	Novel mutations in sporadic typical carcinoids of the lung (lung-TC): Tumor genomic profile by next generation sequencing (NGS).. Journal of Clinical Oncology, 2016, 34, 11596-11596.	1.6	0

#	Article	IF	Citations
37	A new prognostic model of survival in second-line targeted therapy (TT) for metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2016, 34, e16113-e16113.	1.6	0
38	Systematic review and meta-analysis of phase I/II targeted therapy combined with radiotherapy in patients with glioblastoma multiforme: quality of report, toxicity, and survival. Journal of Neuro-Oncology, 2015, 123, 307-314.	2.9	16
39	Flexible modeling of disease activity measures improved prognosis of disability progression in relapsing–remitting multiple sclerosis. Journal of Clinical Epidemiology, 2015, 68, 307-316.	5.0	5
40	Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection. Journal of Clinical Oncology, 2015, 33, 3439-3446.	1.6	234
41	Intramuscular administration of alfaxalone for sedation in rabbits. Veterinary Record, 2015, 176, 255-255.	0.3	42
42	Plasma miR-200b in ovarian carcinoma patients: distinct pattern of pre/post-treatment variation compared to CA-125 and potential for prediction of progression-free survival. Oncotarget, 2015, 6, 36815-36824.	1.8	29
43	Expression of two parental imprinted miRNAs improves the risk stratification of neuroblastoma patients. Cancer Medicine, 2014, 3, 998-1009.	2.8	11
44	Long–term results of the combination of the N7 induction chemotherapy and the busulfan–melphalan high dose chemotherapy. Pediatric Blood and Cancer, 2014, 61, 977-981.	1.5	43
45	Cyclophosphamide Compared With Ifosfamide in Consolidation Treatment of Standard-Risk Ewing Sarcoma: Results of the Randomized Noninferiority Euro-EWING99-R1 Trial. Journal of Clinical Oncology, 2014, 32, 2440-2448.	1.6	136
46	ERCC1 Isoform Expression and DNA Repair in Non–Small-Cell Lung Cancer. New England Journal of Medicine, 2013, 368, 1101-1110.	27.0	342
47	Pooled Analysis of the Prognostic and Predictive Effects of *KRAS* Mutation Status and *KRAS* Mutation Subtype in Early-Stage Resected Non–Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy. Journal of Clinical Oncology, 2013, 31, 2173-2181.	1.6	270
48	Mesenchymal Transition and PDGFRA Amplification/Mutation Are Key Distinct Oncogenic Events in Pediatric Diffuse Intrinsic Pontine Gliomas. PLoS ONE, 2012, 7, e30313.	2.5	200
49	Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology, 2006, 43, 548-555.	7.3	149
50	Myocardial Injury in Critically Ill Patients. Chest, 2005, 128, 2758-2764.	0.8	83
51	Patterns of Surveillance Practices After Curative Surgery for Colorectal Cancer in a French Population. Diseases of the Colon and Rectum, 2005, 48, 1890-1899.	1.3	25
52	Comparison of Cox's and relative survival models when estimating the effects of prognostic factors on disease-specific mortality: a simulation study under proportional excess hazards. Statistics in Medicine, 2005, 24, 3887-3909.	1.6	18